Mark Jacobson, M.A., is the Chief Operating Officer at Axsome Therapeutics, Inc., a biopharmaceutical company focused on developing novel therapies for central nervous system disorders. With a strong background in the pharmaceutical industry, Jacobson has been instrumental in driving Axsome's operational strategies and growth. He holds a Master of Arts degree, which has equipped him with the knowledge and skills to excel in his role. Before joining Axsome Therapeutics, Jacobson held various leadership positions at other pharmaceutical companies, where he honed his expertise in operations, business development, and strategic planning. His experience in these areas has been crucial in guiding Axsome through its clinical development stages and towards commercialization of its innovative treatments. At Axsome, Jacobson oversees the company's day-to-day operations, ensuring that the organization runs efficiently and effectively as it works to bring new therapies to patients in need. As COO, Mark Jacobson has played a key role in several of Axsome's significant achievements, including the successful advancement of the company's pipeline and the expansion of its clinical programs. His leadership has been vital in navigating the complex landscape of drug development and regulatory affairs. Jacobson's strategic vision and operational expertise continue to be invaluable assets to Axsome Therapeutics as the company strives to make a meaningful impact on the lives of patients with central nervous system disorders.